RxDoctor Payments Data

Karen Watts

Family · Yuma, AZNPI 1043295405

Payments from drug & device makers

$559in general payments, 2019–2025

Across 44 payments — averaging $12.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$173
  • Novo Nordisk$163
  • Lilly USA, LLC$72
  • Xeris Pharmaceuticals, Inc.$36
  • Chiesi USA, Inc.$22
  • Recordati_rare_diseases_inc.$19
  • plus $74 from 5 others

What the payments were for

  • Food & beverage$559100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$559 in reported general payments places this provider in the 55th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$25,957
Medicare patients
99
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$92,087
TrulicityDulaglutide37$41,575
EliquisApixaban32$35,269
MounjaroTirzepatide24$31,233
Tresiba Flextouch U-200Insulin Degludec27$30,636
FarxigaDapagliflozin Propanediol11$16,600
Breo ElliptaFluticasone/Vilanterol18$10,444
Tresiba Flextouch U-100Insulin Degludec12$8,726
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$7,996
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$6,035
ButransBuprenorphine11$5,942
Insulin Lispro Kwikpen U-100Insulin Lispro12$4,524
Levothyroxine Sodium238$3,081
Albuterol Sulfate HfaAlbuterol Sulfate62$2,806
Atorvastatin Calcium224$2,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$163$92,08771 claims
Lilly USA, LLCTrulicity, Mounjaro$72$72,80861 claims
AstraZenecaFarxiga$14$16,60011 claims
AbbVieSynthroid$173$1,49814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,119 family providers in Arizona.

Other family in Yuma

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →